The BEMA drug delivery technology consists of a small, bioerodible polymer film for application to the mucosal membranes (inner lining of cheek). BEMA films were designed to rapidly deliver a dose of drug across the mucous membranes for time sensitive conditions or to facilitate administration of drugs with poor oral (pill) absorption.
BEMA films are designed to:
- Adhere to oral mucosa in less than 5 seconds
- Optimize delivery across the oral mucosa
- Completely dissolve
The first product to be developed and marketed using the BEMA technology was Onsolis (fentanyl buccal soluble film). Following the successful development and approval of the first product utilizing the BEMA technology, we began to apply the same technology to improve the delivery of other therapies, such as buprenorphine and buprenorphine/naloxone. The BEMA technology may also be developed with other active drugs, particularly in conditions where rapid delivery of drug is important, oral dosing is not optimal, or where intravenous line or injections are unavailable or not practical. BDSI owns the worldwide rights to the BEMA drug delivery technology.